MedTech news

MedTech news roundup April

Posted on by Congenius

This month’s roundup includes an update on the EU Commission’s joint implementation plan for IVDR, guidance from the MDCG on SSCPs, EUDAMED updates, as well as news from the FDA, China’s NMPA, and Australia’s TGA. Read on for more…

News from the EU

EU Commission publishes updated joint implementation plan for IVDR

The EU Commission has published a joint implementation and preparedness plan for Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR).

The Joint Implementation Plan is the result of review by the MDCG including the relevant sub-groups, with input from stakeholders. As well as setting the priorities, the Plan will serve as a living document to monitor their implementation. The status and timelines for each item are updated ongoing to reflect the progress of the work. You can download the updated plan here.

MDCG releases guidance on SSCP creation

The MDR requires medical device manufacturers to draw up a Summary of Safety and Clinical Performance (SSCP) for implantable devices and class III devices (other than custom-made or investigational devices). The SSCP is then validated by a notified body and made available to the public via EUDAMED.

The MDCG has released a document to provide guidance on the presentation, content, and validation of the SSCP. Read the guidance here.

EUDAMED update: Updated technical documentation now available

We’ve been keeping up to speed on the progress of EUDAMED since December 2020, when the first module on Actors Registration was released. In October 2021, the second and third EUDAMED modules – regarding UDI / Device registration, and Notified Bodies & Certificates, were made available.

This month, updated technical documentation for the second and third modules has been made available. For more information on the technical documentation for the UDI / Device registration module click here, and similarly for the Notified Bodies & Certificates module technical documentation, click here.

Updates from the US

FDA releases final guidance regarding Safety and Performance Based Pathway

The FDA has published final guidance on performance criteria for the Safety and Performance Based Pathway regarding denture base resins, facet screw systems, surgical sutures, and orthopaedic fracture fixation plates.

The guidance documents provide the FDA’s recommendations on performance criteria to support premarket submissions for each of these medical products in the Safety and Performance Based Pathway.

Under this framework, those planning to submit a 510(k) using the Safety and Performance Based Pathway for these products will have the option to use the performance criteria proposed in the respective final guidance documents to support substantial equivalence, rather than a direct comparison between the performance of the subject device and a predicate device. The recommendations are intended to promote consistency and facilitate efficient review of submissions.

You can access each of the guidance documents via the links below:

FDA publishes draft guidance on Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions

The FDA’s recently published draft guidance is intended to provide recommendations to industry regarding cybersecurity device design, labelling, and the documentation to be included in premarket submissions for devices with cybersecurity risk. The recommendations aim to facilitate an efficient premarket review process and help ensure that marketed medical devices are sufficiently resilient to cybersecurity threats. Access the draft guidance here.

The latest from Asia-Pacific

China: All Class III Devices & IVDs subject to UDI from 1 June 2022

China’s NMPA has announced that Unique Device Identification (UDI) will be implemented with all Class III devices and IVDs, effective from 1 June 2022.

69 high-risk class III devices were included in the UDI application for the First Group of Devices, which started from 1 January 2021. This latest announcement means the remainder of Class III devices and IVDs will now follow suit. Find out more here.

China: 23 Mandatory Standards to be issued in 2022

On 14 April, the NMPA issued the “2022 Medical Device Industry Standards Revisions Plan”. The plan includes 23 mandatory and 93 recommended standards. The Standards Revisions aim to facilitate local type testing and regulatory submission by manufacturers and intend to make Chinese standards more consistent with international standards. Read more here.

China: NMPA & China Health Commission introduce GCP

The NMPA and China Health Commission have released the “Quality Management Practice Specification for Clinical Trials of Medical Devices”, which will be implemented from 1 May 2022.

The “China GCP” covers the entire process of medical device clinical trials, including design, implementation, supervision, inspection, data collection, recording, preservation, analysis, summary, and reporting.

It reflects the latest international requirements, referring to documents from the IMDRF such as MDCE WG/N57 FINAL:2019. The specification also introduces the concept of multi-regional clinical trials in different countries or regions, which facilitates the market access of innovative imported products. Find out more here.

Australia: TGA issues update on 2021 Advertising Code regarding hard copy ads

Australia’s Therapeutic Goods Administration (TGA) has updated advertisers on the transitional arrangements regarding the 2021 Advertising Code, specifically in relation to stock of hard copy ads.

The Therapeutic Goods Advertising Code Instrument 2021 came into effect on 1 January 2022. The 2021 Code repeals and replaces the Therapeutic Goods Advertising Code (No.2) 2018 (2018 Code). A transition period applies until 30 June 2022, during which time advertisers can comply with either the 2021 Code or the 2018 Code. Find out more here.

That concludes our April MedTech news. Check back in May for more updates.

Found this useful? To receive our MedTech updates direct to your inbox, you can subscribe to our monthly Knowledge update.

Related News & Knowledge

×

Get in touch

If you have a challenge that you think we could help with, please feel free to get in touch by filling out our contact form or by giving us a call. We look forward to speaking with you!

Congenius AG
Riedstrasse 1
CH-8953 Dietikon

e: [email protected]
t: +41 44 741 04 04

    ×

    Request
    a demo

    Find out more about QMgeniuS by requesting a demo.

    Simply fill out your details and click “Request a demo", then a member of the team will get back to you shortly.

    Alternatively, feel free to give us a call on +41 44 741 04 04 to start the conversation. We look forward to hearing from you!

      ×

      Subscribe to our
      monthly knowledge update

      Stay informed and up to date with the latest industry news delivered direct to your inbox. You can tailor your preferences to prioritise what you'd like to hear about each month; be it MedTech news headlines, fact sheet resources on the latest regulations or longer articles covering timely topics across the wider MedTech industry.

      By clicking subscribe, you are signing up to receive a monthly newsletter from us containing MedTech news, industry insights and more from Congenius. Subscribing also gives you full access to all topical content on our website. For information on how your data is managed, see our privacy policy.